Core Viewpoint - Alvotech intends to list Swedish Depository Receipts (SDRs) on Nasdaq Stockholm to broaden its investor base and enhance visibility among Nordic and European institutional investors following the acquisition of Xbrane Biopharma AB's R&D operations [2][3][8] Offering Details - The Offering will be directed solely into Sweden during an application period from May 9–16, 2025, with a maximum price of SEK 90 per SDR [6][12] - The gross proceeds are estimated to be approximately SEK 30 million, with 441,600 SDRs offered, each representing one Share [6][12] - The first day of trading on Nasdaq Stockholm is expected to be May 19, 2025 [6][12] Strategic Importance - The acquisition of Xbrane's R&D operations is a strategic priority to enhance Alvotech's R&D capabilities and establish a strong presence in the Swedish life-science sector [5][8] - The integration of Xbrane's workforce will expand Alvotech's scientific and innovation capabilities, allowing access to a broader talent pool [5][8] Market Positioning - The listing on Nasdaq Stockholm is expected to strengthen Alvotech's recognition in Nordic and European markets, improving access to regional capital and attracting a broader base of institutional and retail investors [3][8] - Alvotech aims to be a global leader in the biosimilar space, with a current pipeline that includes nine disclosed biosimilar candidates targeting various diseases [13][14] Investor Engagement - A free conversion period will be offered to existing shareholders to convert their Shares into SDRs, with conversion fees covered by Alvotech for one year from the first trading day [9][10] - A prospectus detailing the Offering has been published and is available on Alvotech's website and other financial platforms [10][11]